Interleukins in cancer: from biology to therapy

D Briukhovetska, J Dörr, S Endres, P Libby… - Nature Reviews …, 2021 - nature.com
Interleukins and associated cytokines serve as the means of communication for innate and
adaptive immune cells as well as non-immune cells and tissues. Thus, interleukins have a …

[HTML][HTML] A narrative review of tumor-associated macrophages in lung cancer: regulation of macrophage polarization and therapeutic implications

SS Sedighzadeh, AP Khoshbin, S Razi… - … lung cancer research, 2021 - ncbi.nlm.nih.gov
Lung cancer is the deadliest malignancy worldwide. An inflammatory microenvironment is a
key factor contributing to lung tumor progression. Tumor-Associated Macrophages (TAMs) …

Infectious complications of biological and small molecule targeted immunomodulatory therapies

JS Davis, D Ferreira, E Paige, C Gedye… - Clinical microbiology …, 2020 - Am Soc Microbiol
The past 2 decades have seen a revolution in our approach to therapeutic
immunosuppression. We have moved from relying on broadly active traditional medications …

[HTML][HTML] Interleukin-1 (IL-1) and the inflammasome in cancer

V Pretre, D Papadopoulos, J Regard, M Pelletier… - Cytokine, 2022 - Elsevier
Numerous preclinical and clinical studies have demonstrated the significant contribution of
inflammation to the development and progression of various types of cancer. Inflammation in …

Causal relationships between inflammatory factors and multiple myeloma: a bidirectional Mendelian randomization study

Q Wang, Q Shi, J Lu, Z Wang… - International Journal of …, 2022 - Wiley Online Library
Abstract Changes in serum inflammatory factors occur throughout the onset and multiple
myeloma (MM) progression, the feedback loops make it harder to distinguish between …

Mesenchymal stromal cell senescence in haematological malignancies

N Plakhova, V Panagopoulos, K Vandyke… - Cancer and Metastasis …, 2023 - Springer
Acute myeloid leukaemia (AML), chronic lymphocytic leukaemia (CLL), and multiple
myeloma (MM) are age-related haematological malignancies with defined precursor states …

A systematic literature review informing the consensus statement on efficacy and safety of pharmacological treatment with interleukin-6 pathway inhibition with …

K Kastrati, D Aletaha, GR Burmester, E Chwala… - RMD open, 2022 - rmdopen.bmj.com
Objectives Informing an international task force updating the consensus statement on
efficacy and safety of biological disease-modifying antirheumatic drugs (bDMARDs) …

Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study …

CO Landgren, A Chari, YC Cohen, A Spencer… - Leukemia, 2020 - nature.com
Current guidelines for smoldering multiple myeloma (SMM) recommend active monitoring
until the onset of multiple myeloma (MM) before initiating treatment or enrollment in a clinical …

NLRP3 and cancer: Pathogenesis and therapeutic opportunities

IW Tengesdal, CA Dinarello, C Marchetti - Pharmacology & Therapeutics, 2023 - Elsevier
More than a decade ago IL-1 blockade was suggested as an add-on therapy for the
treatment of cancer. This proposal was based on the overall safety record of anti-IL-1 …

Obesity and multiple myeloma: Emerging mechanisms and perspectives

A Tentolouris, I Ntanasis-Stathopoulos… - Seminars in Cancer …, 2023 - Elsevier
Obesity is a global pandemic that has been associated with the development of breast,
endometrial, large intestine, renal, esophageal, and pancreatic cancer. Obesity is also …